Abstract
Aims and background:
In recent years, targeted agents have replaced cytokine therapy as the standard of care for patients with metastatic renal cell carcinoma.
Methods and study design:
We report a patient with multiple metastases from renal cell carcinoma treated with cytoreductive surgery and pazopanib.
Results and conclusions:
The treatment resulted in an early and prolonged response, without toxicity.
MeSH terms
-
Adrenal Gland Neoplasms / drug therapy
-
Adrenal Gland Neoplasms / secondary
-
Angiogenesis Inhibitors / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Diaphragm
-
Humans
-
Indazoles
-
Induction Chemotherapy
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology*
-
Male
-
Middle Aged
-
Neoplasm Grading
-
Neoplasm Staging
-
Neoplasms, Muscle Tissue / drug therapy
-
Neoplasms, Muscle Tissue / secondary
-
Pyrimidines / therapeutic use*
-
Sulfonamides / therapeutic use*
-
Time Factors
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Indazoles
-
Pyrimidines
-
Sulfonamides
-
pazopanib